MedTrace Logo

Primary Lymphedema and Mutation CELSR1 (Cadherin EGF LAG Seven-pass G-type Receptor 1)

NCT04919655 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2021-06-09

No results posted yet for this study

Summary

The investigators will describe the expression of mutation CELSR1 with codon stop and amino acids substitution mechanism in primary lymphedema, in both clinical examination and imaging exploration

Conditions

  • Primary Lymphedema

Sponsors & Collaborators

  • GEHU - Duve Institute - Bruxelles

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • MESTRE GODIN Sandrine · University Hospital, Montpellier

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-02-01
Completion
2022-02-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04919655 on ClinicalTrials.gov